Table 1.
Study cohort and CTA findings (n = 12 patients).
| Cohort Profile | ||
| Age (years) | 54.8 ± 22 | |
| Females | 4 (33.3%) | |
| BMI (kg/cm2) | 23.05 ± 3.35 | |
| (range, 17.6–27.5) | ||
| Overweight > 24 kg/m2 | 4 (33.3%) | |
| Obese > 30 kg/m2 | 0 (0%) | |
| Cardiovascular risk factors | ||
| Arterial Hypertension | 4 (33.3%) | |
| Smoking | 0 (0%) | |
| Positive family history | 0 (0%) | |
| Dyslipidemia | 1 (8.3%) | |
| Diabetes | 2 (16.6%) | |
| Comorbidities | ||
| Atrial fibrillation | 1 (8.3%) | |
| COPD | 1 (8.3%) | |
| Acute congestive heart failure | 1 (8.3%) | |
| Medication | ||
| Antihypertensive | 4 (33.3%) | |
| Anticoagulation | 1 (8.3%) NOAK | |
| 1 (8.3%) clopidogrel | ||
| Statin | 1 (8.3%) | |
| Time to positive RT-PCR for SARS-CoV-2 | 15.1 days (range, 0–51) | |
| Clinical presentation | ||
| Acute, unstable patients | 4 (33.3%) | |
| Stable patients | 8 (66.6%) | |
| Hs-troponin max. in acute patients (n = 4) | 1789 ng/dL 50 ng/dL 624 ng/dL 30 ng/dL |
|
| CTA findings | ||
| Acute, unstable N = 4 |
Stable N = 8 |
|
| Pericardial effusion | 4 (100%) | 2 (25%) |
| Plaque rupture/ACS | 1 (25%) | 0 (0%) |
| MINOCA | 2 (50%) | 0 (0%) |
| Hyperenhancing myocardium | 1 (25%) | 0 (0%) |
| Perivascular inflammation (PCAT+) | 4 (100%) | 2 (25%) |
| Coronary artery disease by CTA | 1 (25%) | 4 (50%) |
| Nonobstructive (<50% stenosis) | 0 (0%) | 2 (25%) |
| Obstructive (>50% stenosis) | 1 (25%) | 2 (25%) |
| Diffuse vessel wall irregularities | 2 (50%) | 3 (37.5%) |
| Focal ectasia | 0 (0%) | (12.5%) |
Abbreviations: MINOCA = myocardial infarction and non-obstructive coronary artery disease. PCAT = pericoronary fat attenuation. ACS = acute coronary syndrome. CTA = computed tomography angiography. COPD = chronic obstructive pulmonary disease. BMI = body mass index. Hs = high sensitivity. NOAK = novel oral anticoagulant.